CClinicalTrials.gg
RecruitingNCT07156890SENTINELUpdated Sep 5, 2025

Surveillance of Respiratory Viruses in Healthcare and Animal Workers

An observational study in Respiratory Viruses, sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Erasmus Medical Center · Observational

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Study summary

Outbreaks with viruses occur continuously, and novel viruses or new variants of existing viruses can surface after a zoonotic event or human-to-human transmission. This project proposal is designed to detect early circulation of (novel) respiratory viruses in both symptomatic and asymptomatic participants, either by direct detection of the virus or changes in local or systemic immunity. Additionally, SENTINEL will provide information on infectivity and (protective) immune responses in viral outbreaks or vaccination campaigns.

Read the detailed description

A well-designed surveillance study in specific cohorts can serve as an early warning system for (1) the introduction of novel viruses (or variants) in the human population, (2) viral immune escape from pre-existing immunity, or (3) virus evolution into more pathogenic variants. Here, we propose prospective sampling of two sentinel groups with high-risk-of exposure to circulating respiratory viruses for the monitoring of both symptomatic and asymptomatic infections, and immune responses to those infections. Hospital staff (HCW) were shown to be good sentinels for the early detection of respiratory viruses, due to their close contact with patients (or colleagues) with respiratory symptoms. Previous studies in HCW during the COVID-19 pandemic have shown that they are a motivated study population, in which sampling at multiple time-points is feasible if the location is close to work and easily accessible. Other interesting sentinels for respiratory viruses are animal workers (AW), as they are exposed to various animal species and infectious viruses, including respiratory viruses with zoonotic potential. History has shown that most major disease outbreaks were preceded by animal-to-human transmission events that remained undetected until large scale human-to-human transmission occurred. The COVID-19 outbreak is the most recent and devastating example. Similarly, the current extensive transmission of influenza virus H5Nx is of concern and has already spilled over into humans on several occasions. Widespread transmission spillover events to mammals could allow the virus to gain mammalian adaptation. In this prospective SENTINEL study, we propose (self)-sampling of participants (starting just before the 2024 respiratory season), during symptomatic infections to identify and genomically characterize the causative respiratory virus. Follow-up visits will be planned to monitor induced local and systemic immune responses. In addition, we propose periodic sampling of participants to assess changes in local and systemic immune parameters caused by unnoticed/asymptomatic infections with respiratory viruses. Finally, participants will be invited for follow up visits after vaccination against respiratory viruses to monitor vaccine induced responses.

This proposal is unique, as we propose to establish biobanks that include paired samples from the upper respiratory tract and peripheral blood, allowing us to study both local and systemic immunity after infection and/or vaccination. More knowledge on local immunity could be crucial for future vaccine design, and application of vaccines in the respiratory tract. SENTINEL will establish a framework that facilitates early detection of viruses that would otherwise stay under the radar until surfacing due to large scale human-to-human transmission. The rapid genomic characterization and isolation of infectious virus will support rapid development of diagnostic assays, giving a head start in case of (re)emergence of a respiratory virus. Additionally, collecting clinical samples over a prolonged period will yield a valuable biobank of blood samples, respiratory tract samples and viruses, of crucial value for future research and/or (retrospective) analysis of respiratory viruses and immune responses directed against these viruses.

02

Conditions studied

  • Respiratory Viruses

Keywords

  • healthcare workers
  • respiratory viruses
  • pandemic preparedness
  • virus-specific immunity
  • surveillance
  • vaccines
03

In context

Lead sponsor

Erasmus Medical Center is the lead sponsor of 466 studies on the registry; 179 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals working at healthcare facilities or facilities with animals (e.g. farms, bird ringers, or slaughterhouses). We will include an average of 250 participants per year, over a maximum of 5 years. 1,000 participants will be recruited in total for the study.

Inclusion criteria

  • 18 years or older
  • Health care workers with or without direct patient contact
  • Animal workers with or without direct animal contact

Exclusion criteria

Exclusion Criteria:

  • \<18 years
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Target follow-up
60 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Health care workers

    Hospital staff with and without direct contact to patients (HCW)

  • Animal workers

    Animal workers with direct contact to animals (AW)

06

What researchers measure

Primary outcomes

  1. Main study endpoint

    Identification of circulating respiratory viruses by targeted molecular testing in symptomatic participants

    Time frame: 60 months

  2. Main study endpoint

    Identification of circulating respiratory viruses by metagenomic sequencing in symptomatic participants

    Time frame: 60 months

  3. Main study endpoint

    Identification of circulating respiratory viruses by virus culture in symptomatic participants

    Time frame: 60 months

  4. Main study endpoint

    Longitudinal monitoring of local immune responses, for example by, but not limited to, quantitative, qualitative and/or functional antibody assays (ELISA, VNT, PRNT) to detect changes as a proxy for asymptomatic exposure to respiratory viruses.

    Time frame: 60 months

  5. Main study endpoint

    Longitudinal monitoring of systemic immune responses, for example by, but not limited to, quantitative, qualitative and/or functional antibody assays (ELISA, VNT, PRNT) to detect changes as a proxy for asymptomatic exposure to respiratory viruses.

    Time frame: 60 months

Secondary outcomes

  1. Secondary study endpoint

    Evaluating antibody effector function analyses, detection of virus-specific B-cell and T-cell subset analyses by flow cytometry.

    Time frame: 60 months

  2. Secondary study endpoint

    Document symptoms, disease severity, disease duration and disease burden of respiratory tract infections using questionnaires

    Time frame: 60 months

  3. Secondary study endpoint

    Understand virus spill-over risks between humans and animals by sampling of animal care workers

    Time frame: 60 months

  4. Secondary study endpoint

    Isolate and expand rare and/or new virus (variants) variants from clinical samples by virus culture for biobanking and future research like the development of new assays or preparation of virus stocks for in vivo or in vitro studies.

    Time frame: 60 months

  5. Secondary study endpoint

    Biobanking to enable retrospective analysis, for instance to identify earlier circulation in case of a (re)emerging (new) respiratory virus (variant).

    Time frame: 60 months

07

Study locations

1 of 1 sites recruiting
  • ErasmusMC
    Rotterdam, South Holland 3015GD, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07156890
Lead sponsor
Erasmus Medical Center
Responsible party
Corine Geurts van Kessel (Medical microbiologist, Erasmus Medical Center) — Principal investigator
First posted
Sep 5, 2025
Start date
Aug 19, 2024
Primary completion
Aug 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
Sep 5, 2025

Study contacts

Corine H. Geurts van Kessel, Dr
Contact
c.geurtsvankessel@erasmusmc.nl
+31643271384

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion